Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Plasma osteoprotegerin and breast cancer risk in BRCA1 and BRCA2 mutation carriers.

Oncotarget - 27 Dec 2016

Odén Lovisa, Akbari Mohammad, Zaman Tasnim, Singer Christian F, Sun Ping, Narod Steven A, Salmena Leonardo, Kotsopoulos Joanne

Abstract excerpt

Emerging evidence suggests a role of receptor activator of nuclear factor κB (RANK)/RANK ligand (RANKL) signaling in breast cancer development. Lower osteoprotegerin (OPG) levels, the endogenous decoy receptor for RANKL which competes with RANK for binding of RANKL, has been reported among BRCA mutation carriers. Whether low OPG levels contribute to the high breast cancer risk in this population is unknown. OPG...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to BRCA1 Protein
Share to BRCA2 Protein

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Breast Neoplasms

Share to Heterozygote

Share to Kaplan-Meier Estimate

Share to Osteoprotegerin

Share to Proportional Hazards Models

Share to Risk Assessment

Source

Open in PubMed Open full text

Identifiers

PMID: 27893411
DOI: 10.18632/oncotarget.13417
PMCID: PMC5349945

Genes

BRCA1
BRCA2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Plasma osteoprotegerin and breast cancer risk in BRCA1 and BRCA2 mutation carriers.PMID 27893411Read ↗

Osteoprotegerin (OPG), The Endogenous Inhibitor of Receptor Activator of NF-κB Ligand (RANKL), is Dysregulated in BRCA Mutation Carriers.Semantic proximity Read ↗

Can we prevent BRCA1-associated breast cancer by RANKL inhibition?Semantic proximity Read ↗

The association between RANKL and Osteoprotegerin gene polymorphisms with breast cancer.Semantic proximity Read ↗

RANKL/OPG in Breast Cancer - Extending Its Territory to BRCA Mutation Carriers.Semantic proximity Read ↗

Genetic polymorphism of the OPG gene associated with breast cancer.Semantic proximity Read ↗

RANKL/RANK: from bone loss to the prevention of breast cancer.Semantic proximity Read ↗

The prognostic role of RANK SNP rs34945627 in breast cancer patients with bone metastases.Semantic proximity Read ↗

RANKL and CSF-1 are elevated in periovulatory follicular fluid of BRCA1 mutation carriers and increase proinflammatory signaling in fallopian tube epithelial cells.Semantic proximity Read ↗

RANKL/RANK control Brca1 mutation- .Semantic proximity Read ↗

Physical activity and Mediterranean diet as potential modulators of osteoprotegerin and soluble RANKL in gBRCA1/2 mutation carriers: results of the lifestyle intervention pilot study LIBRE-1.Semantic proximity Read ↗

Polymorphisms in the RANK/RANKL genes and their effect on bone specific prognosis in breast cancer patients.Semantic proximity Read ↗

RANKL and OPG Polymorphisms Are Associated with Aromatase Inhibitor-Related Musculoskeletal Adverse Events in Chinese Han Breast Cancer Patients.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.